GOALS OF WORK: Advanced colorectal cancer (CRC) has recently been treated with monoclonal antibodies, such as cetuximab. Skin toxicity is a peculiar side effect of cetuximab that may induce patients to interrupt therapy if it becomes serious. This study investigates the psychological and social sequelae of skin rash. MATERIALS AND METHODS: Patients affected by advanced CRC and treated with cetuximab-based therapy entered the trial. The following questionnaires were used: the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) to measure quality of life (QoL) and the Psychological Distress Inventory (PDI). A single item regarding social avoidance was added with a three-point Likert scale. Toxicity was assessed using the National Cancer Institute Criteria (NCI-2). MAIN RESULTS: Eighty patients were recruited; 41% presented psychological distress. As regards social avoidance, 53% of patients answered that they did not avoid going out at all. The rest of the sample answered that they "very much" (22%) or "somewhat" (25%) avoided going out. Psychological distress and social avoidance were not correlated to skin rash, but only to QoL. CONCLUSION: Skin rash was not found to impact patients' psychological status or social life. Two likely explanations for this finding were that (a) patients with advanced cancer consider skin rash as a part of the complex suffering caused by cancer and (b) patients are encouraged by oncologists to continue treatment because skin rash is indicative of response to therapy. This expectation brings hope and helps patients bear the drug-related side effects.
GOALS OF WORK: Advanced colorectal cancer (CRC) has recently been treated with monoclonal antibodies, such as cetuximab. Skin toxicity is a peculiar side effect of cetuximab that may induce patients to interrupt therapy if it becomes serious. This study investigates the psychological and social sequelae of skin rash. MATERIALS AND METHODS:Patients affected by advanced CRC and treated with cetuximab-based therapy entered the trial. The following questionnaires were used: the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) to measure quality of life (QoL) and the Psychological Distress Inventory (PDI). A single item regarding social avoidance was added with a three-point Likert scale. Toxicity was assessed using the National Cancer Institute Criteria (NCI-2). MAIN RESULTS: Eighty patients were recruited; 41% presented psychological distress. As regards social avoidance, 53% of patients answered that they did not avoid going out at all. The rest of the sample answered that they "very much" (22%) or "somewhat" (25%) avoided going out. Psychological distress and social avoidance were not correlated to skin rash, but only to QoL. CONCLUSION:Skin rash was not found to impact patients' psychological status or social life. Two likely explanations for this finding were that (a) patients with advanced cancer consider skin rash as a part of the complex suffering caused by cancer and (b) patients are encouraged by oncologists to continue treatment because skin rash is indicative of response to therapy. This expectation brings hope and helps patients bear the drug-related side effects.
Authors: Anna Liza C Agero; Stephen W Dusza; Cristiane Benvenuto-Andrade; Klaus J Busam; Patricia Myskowski; Allan C Halpern Journal: J Am Acad Dermatol Date: 2006-10 Impact factor: 11.527
Authors: A E Bonomi; D F Cella; E A Hahn; K Bjordal; B Sperner-Unterweger; L Gangeri; B Bergman; J Willems-Groot; P Hanquet; R Zittoun Journal: Qual Life Res Date: 1996-06 Impact factor: 4.147
Authors: Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2005 Jan-Feb Impact factor: 508.702
Authors: Keith G Wilson; Harvey Max Chochinov; Christine J McPherson; Katerine LeMay; Pierre Allard; Srini Chary; Pierre R Gagnon; Karen Macmillan; Marina De Luca; Fiona O'Shea; David Kuhl; Robin L Fainsinger Journal: J Clin Oncol Date: 2007-05-01 Impact factor: 44.544
Authors: T Kogawa; A Doi; M Shimokawa; T M Fouad; T Osuga; F Tamura; T Mizushima; T Kimura; S Abe; H Ihara; T Kukitsu; T Sumiyoshi; N Yoshizaki; M Hirayama; T Sasaki; Y Kawarada; S Kitashiro; S Okushiba; H Kondo; Y Tsuji Journal: Target Oncol Date: 2014-05-27 Impact factor: 4.493
Authors: Ilufredo Y Tantoy; Anand Dhruva; Janine Cataldo; Alan Venook; Bruce A Cooper; Steven M Paul; Jon D Levine; Yvette P Conley; Frances Cartwright; Kathryn Lee; Fay Wright; Christine Miaskowski Journal: J Gastrointest Oncol Date: 2017-02
Authors: Federica Andreis; Anna Rizzi; Paola Mosconi; Claudia Braun; Luigina Rota; Fausto Meriggi; Maria Mazzocchi; Alberto Zaniboni Journal: Health Qual Life Outcomes Date: 2010-04-15 Impact factor: 3.186
Authors: Dawn Odom; Beth Barber; Lee Bennett; Marc Peeters; Zhongyun Zhao; James Kaye; Michael Wolf; Jeffrey Wiezorek Journal: Int J Colorectal Dis Date: 2010-12-29 Impact factor: 2.571
Authors: Salvatore Siena; Josep Tabernero; Gyorgy Bodoky; David Cunningham; Fernando Rivera; Paul Ruff; Jean Luc Canon; Reija Koukakis; Gaston Demonty; Guy Hechmati; Jean-Yves Douillard Journal: ESMO Open Date: 2016-03-31
Authors: Rossella De Luca; Gianluca Lo Coco; Raffaele Addeo; Silvia Ileana Sara Fattoruso; Annunziata Auriemma; Roberta Paci; Ornella Mistretta; Maria Stella Epifanio; Angela Salvato; Alberto D'Agostino; Giuseppe Cicero Journal: World J Oncol Date: 2021-07-10